Showing 4631-4640 of 5957 results for "".
- Hydrus Microstent Lowers Visual Field Loss by 47%, According to New 5-Year Pivotal Trial Datahttps://modernod.com/news/hydrus-microstent-lowers-visual-field-loss-by-47-according-to-new-5-year-pivotal-trial-data/2480443/Ivantis, developer of the Hydrus Microstent, announced new data from its 5-year HORIZON t
- Centricity Vision Names Todd Pinkney Chief Commercial Officer; Launches New Campaign for Zepto Cataract Surgical Platformhttps://modernod.com/news/centricity-vision-names-todd-pinkney-chief-commercial-officer-launches-new-campaign-for-zepto-cataract-surgical-platform/2480437/Centricity Vision announced that Todd Pinkney has been named chief commercial officer (CCO) and will lead global commercialization of the Zepto Platform. "We're confident that Zepto will have a huge impact on the cataract surgery market," Mr. Pinkney said.
- iSTAR Medical Present Final Results From STAR-II European Trial for MINIject in Glaucoma Patients at AAOhttps://modernod.com/news/istar-medical-present-final-results-from-star-ii-european-trial-for-miniject-in-glaucoma-patients-at-aao/2480433/iSTAR Medical announced final results of the STAR-II European trial for its MIGS device, MINIject. These data show consistently outstanding performance and a favorable safety profile in patients with primary open-angle glaucoma up to 2 years of follow-up. The trial results will be presented at th
- Oculis Announces Patient Dosing in its First Phase 3 Study With OCS-01 Investigational Topical Eye Drop for DMEhttps://modernod.com/news/oculis-announces-patient-dosing-in-its-first-phase-3-study-with-ocs-01-investigational-topical-eye-drop-for-dme/2480432/Oculis SA announced that the first patients have been dosed in its phase 3 DIAMOND trial evaluating the efficacy and safety of OCS-01 in diabetic macular edema (DME). OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone (DSN
- LumiThera Acquires Diopsys, Provider of Light-Based Theranostic Approach to Treat Ocular Diseasehttps://modernod.com/news/lumithera-acquires-diopsys-provider-of-light-based-theranostic-approach-to-treat-ocular-disease/2480430/LumiThera announced its entry into a definitive merger agreement with Diopsys, a provider of modern visual electrophysiology medical devices that help eye care professionals analyze the entire visual pathway for visual and neuro-visual disorders. Under the terms of
- Ziemer USA Announces Partnership With CorneaGenhttps://modernod.com/news/ziemer-usa-announces-partnership-with-corneagen/2480429/Ziemer USA, a wholly owned subsidiary of Switzerland-based Ziemer AG, announced a new partnership with CorneaGen. "We have started an exciting new collaboration with CorneaGen," said David Bragg, President of Ziemer USA & Canada. "Through combined developme
- Abbvie and Regenxbio Announce Collaboration to Advance Gene Therapy for Retinal Diseaseshttps://modernod.com/news/abbvie-and-regenxbio-announce-collaboration-to-advance-gene-therapy-for-retinal-diseases/2480427/AbbVie and Regenxbio announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. RGX-314 is currently being evaluated in
- iVeena Announces Successful Completion of Pre-IND Meeting with FDAhttps://modernod.com/news/iveena-announces-successful-completion-of-pre-ind-meeting-with-fda/2480426/iVeena Delivery Systems announced completion of a pre-investigational new drug (IND) meeting with the FDA regarding the development plan for a novel pharmacologic treatment of pediatric myopia. IVMED-85 enables physiologic crosslinking in the sclera an
- Alcon to Acquire Ivantis, Maker of the Hydrus Microstent for Surgical Glaucomahttps://modernod.com/news/alcon-to-acquire-ivantis-and-its-hydrus-microstent-for-surgical-glaucoma-strengthening-global-ophthalmology-portfolio/2480410/Alcon announced its intention to acquire Ivantis, developer and manufacturer of the Hydrus Microstent. The deal will strenghten Alcon's surgical glaucoma portfolio and allow it to enter the growing MIGS category. Under terms of the deal, Alcon will pay $475 million in upfr
- CooperVision Myopia Control Research Receives Garland W. Clay Awardhttps://modernod.com/news/coopervision-myopia-control-research-receives-garland-w-clay-award/2480405/The American Academy of Optometry has awarded the 2021 Garland W. Clay Award to a team of researchers studying the effectiveness of CooperVision MiSight 1 day contact lenses in slowing the progression of myopia in children (aged 8-12 at the initiation of treatment).